Defining new therapeutics using a more immunocompetent mouse model of antibody-enhanced dengue virus infection

Amelia K. Pinto, James D. Brien, Chia Ying Kao Lam, Syd Johnson, Cindy Chiang, John Hiscott, Vanessa V. Sarathy, Alan D. Barrett, Sujan Shresta, Michael S. Diamond

Research output: Contribution to journalArticle

24 Scopus citations

Abstract

With over 3.5 billion people at risk and approximately 390 million human infections per year, dengue virus (DENV) disease strains health care resources worldwide. Previously, we and others established models for DENV pathogenesis in mice that completely lack subunits of the receptors (Ifnar and Ifngr) for type I and type II interferon (IFN) signaling; however, the utility of these models is limited by the pleotropic effect of these cytokines on innate and adaptive immune system development and function. Here, we demonstrate that the specific deletion of Ifnar expression on subsets of murine myeloid cells (LysM Cre+ Ifnarflox/flox [denoted as Ifnarf/f herein]) resulted in enhanced DENV replication in vivo. The administration of subneutralizing amounts of cross-reactive anti-DENV monoclonal antibodies to LysM Cre+ Ifnarf/f mice prior to infection with DENV serotype 2 or 3 resulted in antibody-dependent enhancement (ADE) of infection with many of the characteristics associated with severe DENV disease in humans, including plasma leakage, hypercytokinemia, liver injury, hemoconcentration, and thrombocytopenia. Notably, the pathogenesis of severe DENV-2 or DENV-3 infection in LysM Cre+ Ifnarf/f mice was blocked by pre-or postexposure administration of a bispecific dual-affinity retargeting molecule (DART) or an optimized RIG-I receptor agonist that stimulates innate immune responses. Our findings establish a more immunocompetent animal model of ADE of infection with multiple DENV serotypes in which disease is inhibited by treatment with broad-spectrum antibody derivatives or innate immune stimulatory agents.

Original languageEnglish (US)
Article numbere01316-15
JournalmBio
Volume6
Issue number5
DOIs
StatePublished - 2015

ASJC Scopus subject areas

  • Microbiology
  • Virology

Fingerprint Dive into the research topics of 'Defining new therapeutics using a more immunocompetent mouse model of antibody-enhanced dengue virus infection'. Together they form a unique fingerprint.

  • Cite this

    Pinto, A. K., Brien, J. D., Lam, C. Y. K., Johnson, S., Chiang, C., Hiscott, J., Sarathy, V. V., Barrett, A. D., Shresta, S., & Diamond, M. S. (2015). Defining new therapeutics using a more immunocompetent mouse model of antibody-enhanced dengue virus infection. mBio, 6(5), [e01316-15]. https://doi.org/10.1128/mBio.01316-15